You ever have that gut‑punch moment where you stare at your portfolio, double‑check the ticker symbol, refresh the chart twice, and whisper to yourself: this can’t be right ? Yeah, that was me last week, watching Novo Nordisk implode like someone pulled the plug out of a billion‑dollar bathtub. Twenty‑plus percent down in a single day, thirty‑something percent down in a week. For a stock that was supposed to be the crown jewel of obesity treatment? That’s not just a red day. That’s a bloodbath. And here’s the thing—I’ll admit it, I was wrong. Not once. Twice. That’s right. The guy who told everyone Novo was bulletproof, who laughed at every bearish report, and who smugly repeated “GLP‑1s are the future” like it was gospel? Yeah, I’m eating crow, with a side of humble pie, washed down with tears of regret. The first time I was wrong, it was because I underestimated operational risk. I saw those sky‑high margins, the Wegovy and Ozempic hype, and thought, what could possibly go wrong? S...